**STUDY AUDIT CHECKLIST**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Principal Investigator: |  | | | | Contact Person  (if different from PI): |  | | |
| Employee/Student#: |  | | Phone: |  | Employee/Student#: |  | Phone: |  |
| Email: |  | | | | Email: |  | | |
| Department: |  | | | | Department: |  | | |
| Campus Address*:* |  | | | | Campus Address: |  | | |
| Co-Investigator(s)  (Name & affiliation or “None”): | |  | | | | | | |
| Title of Study: | |  | | | | | | |

|  |  |
| --- | --- |
| **STUDY STATUS:** |  |
| **#SUBJECTS ENROLLED:** |  |
| **LOCATION OF STUDY:** |  |
| **ALL SITES PI IS DIRECTLY RESPONSIBLE** |  |
| **DATE OF AUDIT:** |  |
| **AUDITOR:** |  |

**Audit worksheets completed for this audit:**

* 1. Regulatory Documentation
* 2. Site Operations
* 3. Protocol Compliance
* 4. Informed Consent Documentation
* 5. Subject Records
* 6. Safety Monitoring
* 7. Drug/Device/Test Article Accountability

# **AUDIT WORKSHEET 1**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **REGULATORY DOCUMENTATION** |

|  |  |
| --- | --- |
| 1. Regulatory documents organized, complete, available:  Yes  No  N/A  Comments: | |
| 2. Protocol, current IRB approved version in study file:  Yes  No  N/A  Comments: |
| 3. Informed Consent Documents (ICD), current IRB-approved version in study file:  Yes  No  N/A  Comments: | |
| 4. Parental Permission Documents, current IRB-approved version in study file:  Yes  No  N/A  Comments: | |
| 5. Assent Document current IRB-approved version in study file:  Yes  No  N/A  Comments: | |
| 6. IDE application/approval:  Yes  No  N/A  Comments: | |
| 7. Investigator Brochure/Device Manual in study file:  Yes  No  N/A  Comments: | |
| 8. IND application/approval:  Yes  No  N/A  Comments: | |
| 9. Food & Drug Administration (FDA) 1571 current, signed, dated, and completed:  Yes  No  N/A  Comments: | |
| 10. All sub-investigators listed on FDA 1572 current, signed, dated, and completed:  Yes  No  N/A  Comments: | |
| 11. All sub-investigators listed on FDA 1572:  Yes  No  N/A  Comments: | |
| 12. Required Curriculum Vitaes (CV) on file (investigators and sub-investigator listed on FDA 1572):  Yes  No  N/A  Comments: | |
| 13. Clinical laboratory certifications on file:  Yes  No  N/A  Comments: | |
| 14. Laboratory normals on file:  Yes  No  N/A  Comments: | |
| 15. Site signature log in study file:  Yes  No  N/A  Comments: | |
| 16. Subject enrollment screening log in study file:  Yes  No  N/A  Comments: | |
| 17. Staff training records in study file:  Yes  No  N/A  Comments: | |
| 18. Sponsor correspondence in study file:  Yes  No  N/A  Comments: | |
| 19. Sponsor monitoring log/reports in study file:  Yes  No  N/A  Comments: | |
| 20. FDA and all study related correspondence in file:  Yes  No  N/A  Comments: | |
| 21. Questionnaire/survey/advertisements/current IRB approved version in study file:  Yes  No  N/A  Comments: | |
| 22. All amendments/modifications/addendums to originally approved protocol or ICD in study file:  Yes  No  N/A  Comments: | |
| 23. Waiver or modification of consent and authorization (HIPAA) current IRB approved version in study file:  Yes  No  N/A  Comments: | |
| 24. All correspondence (e.g., letters, e-mail, ect..) to and from the IRB on file:  Yes  No  N/A  Comments: | |
| 25. Annual IRB continuing renewal application review obtained:  Yes  No  N/A  Comments: | |

# **AUDIT WORKSHEET 2**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **SITE OPERATIONS** |

|  |  |
| --- | --- |
| 1. Documentation of P.I./Co-P.I. involvement in conducting and supervising study:  Yes  No  N/A  Comments: | |
| 2. Responsibilities and tasks delegated to qualified personnel:  Yes  No  N/A  Comments: | |
| 3. P.I./Co-P.I. directly involved in the ICD process:  Yes  No  N/A  Comments: |
| 4. P.I./Co-P.I. or study personnel delegate available by phone 24 hours/day to study participants: Yes No N/A  Comments: |
| 5. Process in place to maintain study subject confidentiality:  Yes  No  N/A  Comments: |
| 6. All investigators and study personnel completed required research training:  Yes  No  N/A  Comments: |

# **AUDIT WORKSHEET 3**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **PROTOCOL COMPLIANCE** |

|  |  |
| --- | --- |
| 1. Inclusion/Exclusion criteria met per IRB approved protocol:  Yes  No  N/A  Comments: | |
| 2. Screening, study treatment/procedures, performed per IRB approved protocol:  Yes  No  N/A  Comments: | |
| 3. Study administered by IRB authorized personnel only and at approved sites:  Yes  No  N/A  (Look for signatures or notes by personnel not on the list, especially in CRFs)  Comments: |
| 4. Only IRB protocol approved concomitant – treatment or medications administered:  Yes  No  N/A  Comments: |
| 5. Modifications to the study protocol prior to IRB approval or exemption:  Yes  No  N/A  Comments: |
| 6. IRB approved study protocol follow-up procedures performed:  Yes  No  N/A  Comments: |
| 7. Drug, Device or test article administration errors:  Yes  No  N/A  Comments: |

# **AUDIT WORKSHEET 4**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **INFORMED CONSENT DOCUMENTATION** |

|  |  |
| --- | --- |
| 1. IRB stamped ICD correct current version used and in study file:  Yes  No  N/A  Comments: | |
| 2. ICD in each patients source document/medical record:  Yes  No  N/A  Comments: | |
| 3. ICD’s signed, dated and witnessed:  Yes  No  N/A  Comments: |
| 4. Parental permission/authorization document signed, dated and witnessed:  Yes  No  N/A  Comments: |
| 5. Assent document signed dated and witnessed:  Yes  No  N/A  Comments: |
| 6. Consent process documented in source document/progress notes:  Yes  No  N/A  Comments: |
| 7. Consent obtained prior to study procedures/and or screening as applicable:  Yes  No  N/A  Comments: |
| 8. Subject or legally authorized representative provided with a copy of the consent document:  Yes  No  N/A  Comments: |
| 9. All additional consent documents signed, dated and witnessed. (e.g., consent to collect/ take/ store, specimens, audio/video images:  Yes  No  N/A  Comments: |

# **AUDIT WORKSHEET 5**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **SUBJECT RECORDS** |

|  |  |
| --- | --- |
| 1. Subject records/source documents organized, readable and secured.:  Yes  No  N/A  Comments: | |
| 2. Subject case history documented to include information, data, and observations of subjects condition at time of enrollment:  Yes  No  N/A  Comments: | |
| 3. Study events and progress notes on the conditions of the subject throughout participation in the study:  Yes  No  N/A  Comments: |
| 4. Data collected in source documents are also recorded on Case Report forms as appropriate or equivalent record:  Yes  No  N/A  Comments: |
| 5. Direct Data entry system is thorough, accurate, complete and captures study events:  Yes  No  N/A  Comments: |
| 6. All copies correspondence with the subject is in the official record:  Yes  No  N/A  Comments: |
| 7. Information, data, observation of subjects condition at end of study:  Yes  No  N/A  Comments: |
| 8. Subject withdrawal form research participation including reason documented:  Yes  No  N/A  Comments: |
| 9. Subject compensation is documented and concurs with the IRB approval for compensation in the informed consent document:  Yes  No  N/A  Comments: |

# **AUDIT WORKSHEET 6**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **SAFETY MONITORING** |

|  |  |
| --- | --- |
| 1.All Adverse Events (AE) reported to the IRB sponsor and appropriate regulatory agency within required timeline requirements:  Yes  No  N/A  Comments: | |
| 2. Serious Adverse Events (SAE) followed to resolution, return to baseline, completion, or judged acceptable by the IRBs and Principal Investigator:  Yes  No  N/A  Comments: | |
| 3. All adverse events recorded in subjects record, source document, and CRF or equivalent:  Yes  No  N/A  Comments: |
| 4. All protocol deviations reported to the IRB, Sponsor and appropriate regulatory agency within required timeline:  Yes  No  N/A  Comments: |
| 5. All Data Safety Monitoring Board (DSMB) reports sent to the IRB:  Yes  No  N/A  Comments: |
| 6. IRB notified of unanticipated problems involving risk to subjects at site:  Yes  No  N/A  Comments: |
| 7. All External SAE, Safety Reports and Med Watch-reports submitted to the IRB within required timeline:  Yes  No  N/A  Comments: |
| 8. Periodic Progress reports sent to the IRB if applicable:  Yes  No  N/A  Comments: |
| 9. IRB approval of any changes in research activity as required by regulations and guidelines:  Yes  No  N/A  Comments: |
| 15. All correspondence (e.g., e-mail, letters) to and from the IRB on file:  Yes  No  N/A  Comments: |

# **AUDIT WORKSHEET 7**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Auditor: |  | Date: |  | IRB# |  |

|  |
| --- |
| **DRUG/DEVICE/TEST ARTICLE ACCOUNTABILITY** |

|  |  |
| --- | --- |
| 1. Records of receipt of drug/device/test articles in study file:  Yes  No  N/A  Comments: | |
| 2. All drugs/devices/test articles secured and stored properly (i.e. temperature log, light protections, etc. as per the IDDF):  Comments:  Yes  No  N/A | |
| 3. Inventory Log – organized, completed, available:  Yes  No  N/A  Comments: |
| 4. Drug/device/test article name, dosage strength, and form type:  Yes  No  N/A  Comments: |
| 5. Lot number  Yes  No  N/A  Comments: |
| 6. Expiration date:  Yes  No  N/A  Comments: |
| 7. Date and quantity dispensed:  Yes  No  N/A  Comments: |
| 8. Amount transferred/returned/destroyed:  Yes  No  N/A  Comments: |
| 9. Date and quantity returned by study participant:  Yes  No  N/A  Comments: |
| 10. Date and quantity returned to sponsor::  Yes  No  N/A  Comments: |
| 11. 24 hour emergency telephone number of Sponsor:  Yes  No  N/A  (Call and see who answers. Is it still the same as the number listed in the IDDF?)  Comments: |
| 12. Chain of custody per regulations or protocol:  Yes  No  N/A  Comments: |
| 13. Drug/device/test article used for protocol purposes only:  Yes  No  N/A  Comments: |
| 14. Drug/device/test article manual/package insert information in file:  Yes  No  N/A  Comments: |